论文部分内容阅读
目的:观察静脉滴注泮托拉唑对消化性溃疡患者胃酸分泌的影响及其安全性。方法:多中心随机开放对照研究。符合标准的消化性溃疡患者随机分为治疗组(29例):静脉滴注泮托拉唑40mg;对照组(29例):静脉滴注奥美拉唑40mg。进行24h胃内pH监测,治疗前后检测血、尿、便常规,肝,肾功能。结果:泮托拉唑治疗组的起效时间(33.5±7.1min)、胃内pH中位数(5.2±2.2)、24h胃内pH≥3(7.9%±7.1%)、≥4(69.1%±5.5%)、≥5(60.5%±6.0%)和≥6(44.6%±6.1%)的时间所占百分比与对照组比较无显著性差异。伴托拉唑治疗组用药后20h内每小时的胃内平均pH均明显高于治疗前。治疗组和对照组均未见明显的药物不良反应发生。结论:静脉滴注泮托拉唑40mg对消化性溃疡患者的胃酸分泌具有较强的抑制作用,且有良好的安全性。
Objective: To observe the effect of intravenous infusion of pantoprazole on gastric acid secretion in patients with peptic ulcer and its safety. Methods: A multicenter, randomized open-label study. Patients with peptic ulcer were randomly divided into treatment group (29 cases): intravenous infusion of pantoprazole 40mg; control group (29 cases): intravenous infusion of omeprazole 40mg. 24h gastric pH monitoring, blood and urine before and after treatment, they routine, liver and kidney function. Results: The onset time (33.5 ± 7.1min), the median gastric pH (5.2 ± 2.2), 24h gastric pH≥3 (7.9% ± 7.1%), ≥4 (69.1% ± 5.5%), ≥5 (60.5% ± 6.0%) and ≥6 (44.6% ± 6.1%) were not significantly different from the control group. The mean intragastric pH of each hour within 20 hours of treatment with the group of tolazole was significantly higher than that before treatment. No significant adverse drug reactions occurred in the treatment group and the control group. Conclusion: Intravenous infusion of pantoprazole 40mg has a strong inhibitory effect on gastric acid secretion in patients with peptic ulcer, and has good safety.